<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35163">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927120</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-17578</org_study_id>
    <nct_id>NCT01927120</nct_id>
  </id_info>
  <brief_title>In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis</brief_title>
  <official_title>In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IL-2 add-back post allogeneic hematopoietic stem cell transplant (HSCT), combined with
      Sirolimus (SIR), Tacrolimus (TAC) will optimize Treg reconstitution and prevent graft versus
      host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) Determine if a GVHD prophylaxis regimen of IL-2/SIR/TAC enhances in vivo Treg
      differentiation and growth; 2) Study the safety and effects of IL-2/SIR/TAC on the incidence
      of acute and chronic GVHD; 3) Evaluate the influence of dual IL-2 supplementation and
      mammalian target of rapamycin (mTOR) inhibition on T cell-specific signaling pathways and
      the polarization of emerging T helper cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>In Vivo Treg Expansion</measure>
    <time_frame>30 days post transplant</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of Treg among blood CD4+ T cells at day 30 after hematopoietic cell transplantation (HCT)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Graft-Versus-Host-Disease</condition>
  <arm_group>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <other_name>Proleukin®</other_name>
    <other_name>(aldesleukin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Orally on day -1.  The dose for loading is 12 mg by mouth (PO)</description>
    <arm_group_label>GVHD Regimen</arm_group_label>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have an available 8/8 human leukocyte antigen (HLA)-A, -B, -C, and
             -DRB1 matched-related or unrelated donor allogeneic hematopoietic peripheral blood
             stem cell graft.

          -  Acute myeloid leukemia, myelodysplasia, acute lymphoblastic leukemia, chronic myeloid
             leukemia, or myeloproliferative neoplasms requiring a matched allogeneic HSCT.

               -  Acute Leukemia (AML or ALL) must be in complete remission defined as:  &lt;5%
                  marrow blasts with no morphologic evidence of leukemia, no peripheral blasts,
                  marrow &gt;20% cellular, and peripheral absolute neutrophil count &gt;1000/µL
                  (platelet recovery is not required).

               -  Myelodysplasia (MDS) and chronic myeloid leukemia (CML):  Must have &lt;5% marrow
                  blasts.

               -  Myeloproliferative neoplasms (MPN):  Must have &lt;5% peripheral / marrow blasts.

          -  Adequate vital organ function:

               1. Left ventricular ejection fraction (LVEF) ≥ 45% by multi gated acquisition
                  (MUGA) scan

               2. Forced expiratory volume at one second (FEV1), forced vital capacity (FVC), and
                  diffusing lung capacity oxygenation (DLCO) ≥ 50% of predicted values on
                  pulmonary function tests

               3. Transaminases (AST, ALT) &lt; 2 times upper limit of normal values

               4. Creatinine clearance ≥ 50 cc/min.

          -  Performance status:  Karnofsky Performance Status Score ≥ 80%

        Exclusion Criteria:

          -  Active infection not controlled with appropriate antimicrobial therapy

          -  History of HIV, hepatitis B, or hepatitis C infection

          -  Anti-thymocyte globulin, alemtuzumab, bortezomib, or cyclophosphamide administered
             within 14 days before or after HCT

          -  Hypersensitivity to recombinant human IL-2

          -  Chronic lymphocytic leukemia, Hodgkin lymphoma, and non-hodgkin lymphoma are excluded
             as these malignancies may express the IL-2 receptor and pose a potential growth
             signal to any present disease.

          -  Sorror's co-morbidity factors with total score &gt;4
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Betts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Betts, MD</last_name>
    <phone>813-745-5410</phone>
    <email>Brian.Betts@moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Betts, MD</last_name>
      <phone>813-745-5410</phone>
      <email>Brian.Betts@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Brian Betts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Pidala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Anasetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcie Riches, MD, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Alsina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ernesto Ayala, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Field, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Janssen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiga Nishihori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Locke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Leonel Ochoa-Bayona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lia Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohamed Kharfan-Dabaja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo Fernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org</url>
    <description>H. Lee Moffitt Cancer Center &amp; Research Institute</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
